Notably, the sorafenib/trametinib combination has already been applied in the context of BRAF class III mutations (83) and advanced hepatocellular carcinoma (84), while first clinical data on naporafenib/trametinib combinations have recently been published for NRAS-driven melanoma (85). Here, NRAS is linked to hepatocellular carcinoma.